The information is based on testing of influenza virus isolates obtained from cell culture, and intends to provide a profile on the proportion of strains with reduced antiviral susceptibility. The date refers to specimen reception by the laboratory. Numbers and trends presented here should be interpreted in light of the small specimen numbers in particular categories.
Antiviral susceptibility testing of influenza A subtype H1 viruses in 2024
| Month | Oseltamivir tested | Oseltamivir - Reduced susceptibility | |
|---|---|---|---|
| No. | % | ||
| Jan | 2 | 0 | 0% |
| Feb | 5 | 2 | 40% |
| Mar | 11 | 1 | 9% |
| Apr | |||
| May | |||
| Jun | |||
| Jul | |||
| Aug | |||
| Sep | |||
| Oct | |||
| Nov | |||
| Dec | |||
Antiviral susceptibility testing of influenza A subtype H3 viruses in 2024
| Month | Oseltamivir tested | Oseltamivir - Reduced susceptibility | |
|---|---|---|---|
| No. | % | ||
| Jan | 14 | 0 | 0% |
| Feb | 10 | 0 | 0% |
| Mar | 6 | 0 | 0% |
| Apr | |||
| May | |||
| Jun | |||
| Jul | |||
| Aug | |||
| Sep | |||
| Oct | |||
| Nov | |||
| Dec | |||
Antiviral susceptibility testing of influenza B viruses in 2024
| Month | Oseltamivir tested | Oseltamivir - Reduced susceptibility | |
|---|---|---|---|
| No. | % | ||
| Jan | 4 | 0 | 0% |
| Feb | 5 | 0 | 0% |
| Mar | 3 | 0 | 0% |
| Apr | |||
| May | |||
| Jun | |||
| Jul | |||
| Aug | |||
| Sep | |||
| Oct | |||
| Nov | |||
| Dec | |||